Urothelial Cancer: What’s New in 2023? [Slides] Targeted and Novel Therapies Nataliya Mar MD - Synopsis below extracted from the video transcript.
Dr. Mar begins the presentation by providing an overview of the disease and its risk factors, which include smoking, exposure to certain chemicals, and chronic bladder inflammation. She then discusses the various treatment options available for urothelial cancer, including surgery, chemotherapy, radiation therapy, and immunotherapy.
Dr. Mar then delves into the latest targeted and novel therapies for urothelial cancer. She explains that targeted therapies are designed to target specific molecules or pathways involved in cancer growth and progression, while novel therapies are new and innovative approaches to treating cancer.
One of the targeted therapies that Dr. Mar highlights is erdafitinib, a drug that targets FGFR3 gene mutations, which are present in approximately 15% of urothelial cancer cases. She also discusses the use of immunotherapy in the treatment of urothelial cancer, including the PD-1 inhibitors pembrolizumab and nivolumab, which have shown promising results in clinical trials.
Read The Full Transcript and Watch The Video Here
Dr. Mar also talks about several novel therapies, including oncolytic viruses, which are viruses that can selectively infect and destroy cancer cells, and CAR T-cell therapy, which involves genetically modifying a patient's own T cells to target cancer cells.
Finally, Dr. Mar emphasizes the importance of personalized medicine in the treatment of urothelial cancer. She explains that by analyzing a patient's tumor at the molecular level, doctors can identify specific genetic mutations or other biomarkers that may make the tumor more susceptible to certain treatments.
Overall, Dr. Mar's presentation provides valuable insights into the latest advancements in the treatment of urothelial cancer and highlights the potential of targeted and novel therapies to improve outcomes for patients with this disease.
